Drug profile · INN
mifepristone
CORLUXIN
mifepristone (CORLUXIN) is a progesterone receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — mifepristone
- US status
- approved
- Class
- Nervous system (NOT)
- Route
- ORAL
- Patents
- 20
- Programs
- 18
- Data quality
- 0.89
Quick answer
mifepristone (CORLUXIN) is a progesterone receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Progesterone receptor antagonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Recent coverage
Supreme Court Ruling on Mifepristone: Implications for Pharma
The Supreme Court's decision to preserve access to mifepristone by mail has significant implications for the pharmaceutical sector, particularly in abortion care.
SCOTUS Restores Telehealth Access to Mifepristone: Implications for Pharma
The recent SCOTUS ruling temporarily restores telehealth access to mifepristone, impacting pharmaceutical strategies and market dynamics. This article explores the implications for pharma teams.
Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit Ruling
Planned Parenthood can continue dispensing Mifepristone by mail and certified pharmacies until May 11 following Supreme Court provisional hold on 5th Circuit ruling.
Pipeline programs
Related & competitor drugs
Related patents
-
US 12097210
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
granted -
US 11969435
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
granted -
US 11173165
Optimizing mifepristone levels for Cushing's patients
granted -
US 10842801
Optimizing mifepristone absorption
granted -
US 10842800
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
granted -
US 10780097
Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted -
US 10660904
Optimizing mifepristone levels for cushing's patients
granted -
US 10500216
Optimizing mifepristone absorption
granted -
US 10495650
Method for differentially diagnosing ACTH-dependent Cushing's syndrome
granted -
US 10314850
Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted -
US 10231983
Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted -
US 10195214
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
granted -
US 10166243
Optimizing mifepristone levels for cushing'S patients
granted -
US 10166242
Optimizing mifepristone levels for Cushing's patients
granted -
US 10151763
Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome
granted -
US 10006924
Method for differentially diagnosing ACTH-dependent cushing's syndrome
granted -
US 9943526
Optimizing mifepristone levels for cushing's patients
granted -
US 9829495
Method for differentially diagnosing ACTH-dependent Cushing's syndrome
granted -
US 8921348
Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
granted -
US 8598149
Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists
granted
Frequently asked questions
What is mifepristone?
mifepristone (CORLUXIN) is a progesterone receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mifepristone?
CORLUXIN is a marketed brand name for mifepristone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mifepristone?
mifepristone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.